lysi plasminogen activator-resist platelet-rich coronari arteri thrombu combin bolu inject recombin tissue-typ plasminogen activ antiplatelet gpiib/iiia antibodi resist coronari occlus thrombu thrombolyt therapi patient acut myocardi infarct due presenc platelet-rich coronari clot reperfus therapi patient develop evalu altern strategi anim model platelet-rich coronari arteri thrombu excis evers reanastomosi cm segment left circumflex coronari arteri anesthet dog heparin antiocoagul blood flow dog thrombot occlus evert segment graft platelet-rich thrombu thrombu platelet-rich erythrocyte-rich zone min min mean SD dog dog group control stabl occlus ultrasound flow probe coronari angiographi observ period group II intraven bolu inject recombin tissue-typ plasminogen activ rt-pa dose mg/kg bodi min interv reperfus dog cyclic reperfus reocclus dog group iii singl intraven bolu inject mg/kg fragment murin monoclon antibodi human platelet gpiib/iiia receptor stabl reperfus dog wherea occlus group IV inject mg/kg rt-pa mg/kg stabl reperfus reocclus dog versu rt-pa alon versu control studi platelet-rich occlus coronari thrombu resist intraven rt-pa resist use dose rt-pa antiplatelet gpiib/iiia receptor antibodi result platelet-rich thrombu resist thrombolyt agent resort mechan recan present dog model use specif strategi dispers resist platelet-rich coronari thrombu 